- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
DTAB agrees change of Allergan India Refresh Tears from prescription drug to OTC - Video
Overview
Granting drug maker Allergan India request to change the category of "Refresh Tears" from prescription drug to over the counter drug, the Drug Technical Advisory Board (DTAB) has agreed to remove the requirement of a prescription from a Registered Medical Practitioner (RMP) in respect of drug product "Refresh Tears" (Carboxymethylcellulose Sodium eye drops IP 0.5% w/v) for its retail sale.
The recommendation was made after considering the proposal made by Allergan India to remove the requirement for a prescription in respect of drug product "Refresh Tears" (Carboxymethylcellulose Sodium eye drops IP 0.5% w/v) sterile opthalmic solution for retail sale.
The drug maker, Allergen, has submitted that its product "Refresh Tears" contains Carboxymethylcellulose Sodium eye drops 0.5% w/v, sterile ophthalmic solution, indicated for the temporary relief of burning, irritation, and discomfort due to dryness of the eyes or exposure to wind or sun, and may be used as a protectant against further irritation, and stated that the product has been marketed since 1998.
For more details check out the link given below:
No Need Of Prescription From Doctors For Refresh Tears: DTAB